Some polymorphic variants of apolipoprotein genes in patients with the first episode of paranoid schizophrenia

Research objective: o study polymorphic variants of the rs670 (APOA1-75 G/A), rs5128 (APOC3 C3238G), rs769452 (APOE Leu28Pro), rs5742904 (APOB R3500Q) genes in patients with the first episode of paranoid schizophrenia living in the Trans-Baikal Territory.

Material and methods. 212 patients with the diagnosis «Paranoid schizophrenia, follow-up period less than a year (ICD code 10 F 20.09)» were examined. The patients were Caucasian race and lived in the Trans-Baikal Territory. The average age of patients was 27±6 years. To form a control group, 152 people were examined, who were comparable in age, gender, and social affiliation with the group of patients. Human genomic DNA was isolated from whole blood leukocytes. rs670 (APOA1-75 G/A), rs5128 (APOC3 C3238G), rs769452 (APOE Leu28Pro), rs5742904 (APOB R3500Q) were studied by real-time polymerase chain reaction.

Results. It was found that patients with the first episode of schizophrenia living in the territory of the Trans-Baikal Territory were 1,3 times more likely to have the genotype G/G SNP rs670 (APOA1-75 G/A) and 1,6 times more likely to have carriers of the heterozygous genotype C/G APOC3 C323G (rs5128). At the same time, the chance of developing schizophrenia in carriers of the G/G SNP rs670 genotype (APOA1-75 G/A) was 1,80, and in carriers of the C/G APOC3 C323G genotype (rs5128) – 2,05. The heterozygous genotype of Leu/Pro SNP APOE (Leu28Pro, rs769425) in patients with schizophrenia was 3,8 times less common, and the frequency of registration of the minor allele was 4,6 times less frequent than in the control group. In the study of SNP rs5742904 (APOB R3500Q) in patients with schizophrenia and in the control group, only carriers of the normal G/G homozygote were found.

Conclusion. In patients with schizophrenia living in the Trans-Baikal Territory, the frequency of occurrence of apolipoprotein gene genotypes differs from healthy people To study the association of polymorphic variants of apolipoprotein genes with metabolic disorders in patients with schizophrenia, further studies are needed.

1. Naderyan Fe'li S., Yassini Ardekani S.M., Fallahzadeh H., Dehghani A. Metabolic syndrome and 10-year risk of cardiovascular events among schizophrenia inpatients treated with antipsychotics. Med J Islam Repub Iran. 2019. 33. :97. DOI: 10.34171/mjiri.33.97.

2. Zhang Y., Wang Q., Reynolds G.P., Yue W., Deng W., Yan H., Tan L., Wang C., Yang G., Lu T., Wang L., Zhang F., Yang J., Li K., Lv L., Tan Q., Li Y., Yu H., Zhang H., Ma X., Yang F., Li L., Chen Q., Wei W., Zhao L., Wang H., Li X., Guo W., Hu X., Tian Y., Ren H., Ma X., Coid J., Zhang D., Li T. Chinese Antipsychotics Pharmacogenomics Consortium. Metabolic Effects of 7Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial. J Clin Psychiatry. 2020. 81(3). 19m12785. DOI: 10.4088/JCP.19m12785.

3. Sahpolat M., Ari M. Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey. Nord J Psychiatry. 2021. 75(1). 73-78. DOI: 10.1080/08039488.2020.1815080.

4. Liu H., Sun Y., Zhang X., Li S., Hu D., Xiao L., Chen Y., He L., Wang D.W. Integrated Analysis of Summary Statistics to Identify Pleiotropic Genes and Pathways for the Comorbidity of Schizophrenia and Cardiometabolic Disease. Front Psychiatry. 2020.11. 256. DOI: 10.3389/fpsyt.2020.00256.

5. Woods A.G., Sokolowska I., Taurines R., Gerlach M., Dudley E., Thome J., Darie C.C. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med. 2012. 16(6). 1184-95. DOI: 10.1111/j.1582-4934.2012.01543.x.

6. Ozornin A.S., Shtan' M.S., Govorin N.V. The prevalence of certain polymorphic loci of apolipoprotein genes in schizophrenic patients in Zabaykalsky krai. Zabaykal'skiy meditsinskiy vestnik. 2017. 2. 154-160. in Russian.

7. Gibbons A.S., Udawela M., Jeon W.J., Seo M.S., Brooks L., Dean B. The neurobiology of APOE in schizophrenia and mood disorders. Front Biosci (Landmark Ed). 2011. 16. 962-79. DOI: 10.2741/3729.

8. Li W. Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study. Schizophr Res Cogn. 2020. 23. 100193. DOI: 10.1016/j.scog.2020.100193.

9. Wu Y., Yu Y., Zhao T., Wang S., Fu Y., Qi Y., Yang G., Yao W., Su Y., Ma Y., Shi J., Jiang J., Kou C. Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome. PLoS One. 2016. 11(1). e0147946. DOI: 10.1371/journal.pone.0147946.